References of "Hiligsmann, Mickaël"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTrends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007)
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Roberfroid, Dominique et al

in Arthritis Care & Research (2012), 64(5), 744-750

Detailed reference viewed: 37 (18 ULg)
Full Text
Peer Reviewed
See detailWhat are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Osteoporosis International (2012, March), 23(S2), 81-82

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailAn economic evaluation of strontium ranelate for the treatment of male osteoporosis
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 305-306

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 312-313

Detailed reference viewed: 28 (5 ULg)
Full Text
Peer Reviewed
See detailQuelles sont les caractéristiques des médicaments les plus importantes pour les patients ostéoporotiques ? Résultats d'une étude qualitative
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Revue du Rhumatisme (2012), 79(S1), 238

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2012), 15(5), 604-12

OBJECTIVES: Medication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to ... [more ▼]

OBJECTIVES: Medication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to evaluate the potential cost-effectiveness of improving patient adherence by using hypothetical behavioral interventions. METHODS: A previously validated Markov microsimulation model was adapted to the Irish setting to estimate lifetime costs and outcomes (fractures and quality-adjusted life-year [QALY]) for three adherence scenarios: no treatment, real-world adherence, and full adherence over 3 years. The real-world scenario employed adherence and persistence data from the Irish Health Services Executive-Primary Care Reimbursement Services pharmacy claims database. We also investigated the cost-effectiveness of hypothetical behavioral interventions to improve medication adherence (according to their cost and effect on adherence). RESULTS: The number of fractures prevented and the QALY gain obtained at real-world adherence levels represented only 57% and 56% of those expected with full adherence, respectively. The costs per QALY gained of real-world adherence and of full adherence compared with no treatment were estimated at euro 11,834 and euro 6,341, respectively. An intervention to improve adherence by 25% would result in an incremental cost-effectiveness ratio of euro 11,511 per QALY and euro 54,182 per QALY, compared with real-world adherence, if the intervention cost an additional euro 50 and euro 100 per year, respectively. DISCUSSION: Poor adherence with osteoporosis medications results in around a 50% reduction in the potential benefits observed in clinical trials and a doubling of the cost per QALY gained from these medications. Depending on their costs and outcomes, programs to improve adherence have the potential to be an efficient use of resources. [less ▲]

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailEconomics in osteoporosis : how can we reconciliate the prescribers and the payer ?
Reginster, Jean-Yves ULg; Hiligsmann, Mickaël ULg

in Osteoporosis International (2012), 23(6), 655-661

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailNominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Annals of the Rheumatic Diseases (2012), 71(3), 597

Detailed reference viewed: 30 (5 ULg)
Full Text
Peer Reviewed
See detailThe importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
Hiligsmann, Mickaël ULg; Boonen, Annelies; Rabenda, Véronique ULg et al

in Expert Reviews of Pharmacoeconomics & Outcomes Research (2012), 12(2), 159-66

Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the ... [more ▼]

Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost-effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost-effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges. [less ▲]

Detailed reference viewed: 37 (7 ULg)
Full Text
Peer Reviewed
See detailA reappraisal of generic bisphosphonates in osteoporosis.
Kanis, J. A.; Reginster, Jean-Yves ULg; Kaufman, J. M. et al

in Osteoporosis International (2012), 23

The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally ... [more ▼]

The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed. INTRODUCTION: The purpose of this study is to review the impact of generic bisphosphonates on effectiveness in the treatment of osteoporosis. METHODS: This study is a literature review. RESULTS: A substantial body of evidence indicates that many generic formulations of alendronate are more poorly tolerated than the proprietary preparations which results in significantly poorer adherence and thus effectiveness. Poorer effectiveness may result from faster disintegration times of many generics that increase the likelihood of adherence of particulate matter to the oesophageal mucosa. Unfortunately, market authorisation, based on the bioequivalence of generics with a proprietary formulation, does not take into account the potential concerns about safety. The poor adherence of many generic products has implications for guideline development, cost-effectiveness and impact of treatment on the burden of disease. CONCLUSIONS: The impact of generic bisphosphonates requires formal testing to re-evaluate their role in the management of osteoporosis. [less ▲]

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailEvolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Roberfroid, D. et al

in Revue du Rhumatisme (2011, December), 78(Suppl. 5), 43-44

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic implications of non-adherence with osteoporosis medications in Ireland
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

Conference (2011, November)

Detailed reference viewed: 6 (1 ULg)
Full Text
See detailInterest of Health Economic Analyses
Hiligsmann, Mickaël ULg

Conference given outside the academic context (2011)

Detailed reference viewed: 8 (3 ULg)